Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

Issue: February 2020
January 10, 2020
1 min read

Rare Pediatric Disease Designation Given to Gene Therapy for Sickle Cell Disease

Issue: February 2020
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA granted rare pediatric disease designation to ARU-1801, an investigational autologous gene therapy, for the treatment of sickle cell disease, according to the agent’s manufacturer.

ARU-1801 (Aruvant/Roivant Sciences) is under development as a possible one-time treatment for sickle cell disease and beta-thalassemia.

The investigational therapy aims to increase functioning red blood cells by inserting a modified fetal hemoglobin gene into the patient’s CD34-positive hematopoietic stem cells through a lentiviral vector.

Previous studies have shown that patients with sickle cell disease with elevated levels of fetal hemoglobin have fewer vaso-occlusive crises and fewer hospitalizations than patients who have only adult hemoglobin.

ARU-1801 was designed to produce a potent gene payload with a reduced-intensity conditioning approach. The therapy delivers gene-encoding fetal hemoglobin that has been modified to optimize oxygen-carrying capacity and anti-sickling properties, according to the manufacturer.

“The FDA’s rare pediatric disease designation for ARU-1801 highlights the large and unmet need currently experienced by patients suffering from sickle cell disease,” Will Chou, MD, CEO of Aruvant, said in a company-issued press release.

“Other investigational gene therapies for sickle cell disease require the use of high-intensity myeloablative conditioning regimens, which are associated with lengthy hospital stays and a host of possibly serious complications,” he said. “Our reduced-intensity conditioning approach aims to provide patients a cure with an improved risk-benefit profile, including a lower risk of infertility and fewer days in the hospital.”

The FDA defines a rare pediatric disease as a disease or condition that is serious or life-threatening and affects fewer than 200,000 children in the United States.

The rare pediatric disease designation makes Aruvant eligible for an FDA priority review voucher for ARU-1801 if the agency approves the investigational therapy’s biologics license application.